Forbion said it brought John McDonald aboard as an operating partner with responsibility for business development and M&A, after McDonald previously served in similar roles at Novo Nordisk, Biogen, and MPM Capital. The move aligns with ongoing venture and growth-stage activity that increasingly depends on partnering and deal execution. Forbion also promoted a broader network of partners, reflecting how European biopharma financiers are focusing on transaction capability alongside portfolio scientific execution.